spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Ataxia 

 HSMN NewsFeed - 5 Jan 2024
Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 20 Jul 2023
Boehringer Ingelheim Receives FDA Approval for NexGard(R) PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Biopharmaceuticals Veterinary FDA
 HSMN NewsFeed - 25 Feb 2022
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 25 Feb 2022
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Feb 2022
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Dec 2021
Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2021
NURTEC(R) ODT Approved In Kuwait For Acute Treatment Of Migraine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Jan 2021
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2020
Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of Niemann Pick Disease Types A and B With PLX-300
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Nov 2020
PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2020
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 29 Jul 2020
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 10 Jun 2020
Biohaven Appoints Bob Hugin to its Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Mar 2020
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Mar 2020
FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 31 Jul 2019
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jul 2019
REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV(R) AAV9 Vector
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 26 Jun 2019
Encoded Therapeutics, Inc. Announces $104 Million Series C Financing to Advance Lead Gene Therapy Program in Dravet Syndrome and Unveils its Precision Gene Therapy Platform
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 30 Aug 2018
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
Biopharmaceuticals
 HSMN NewsFeed - 3 Apr 2018
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2017
Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2017
Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Aug 2017
Jupiter Orphan Therapeutics Receives Orphan Drug Designation for its Trans-Resveratrol Product JOTROL for Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 4 Aug 2017
Biohaven Appoints Julia P. Gregory to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 11 Jul 2017
Nuredis Appoints Julie Anne Smith as Chief Executive Officer to Lead Neurodegenerative Disease Company
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 19 May 2016
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
Biopharmaceuticals Licensing Acquisitions
 HSMN NewsFeed - 10 Sep 2015
Agilis Biotherapeutics Appoints Arthur Tzianabos, Ph.D., to the Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Jul 2015
RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Jul 2015
Voyager Therapeutics Appoints Michael Higgins to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 10 Apr 2015
Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 13 Feb 2015
Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 6 Oct 2014
Claret Medical Announces First Patient Treated in U.S. Pivotal Trial Evaluating Cerebral Protection During Transcatheter Aortic Valve Replacement (TAVR)
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Sep 2014
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 9 Jun 2014
FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Leigh Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2014
AAVLife Raises $12 Million in Series A Financing to Advance Gene Therapy for Friedreich’s Ataxia
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 17 Mar 2014
FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Mar 2014
Edison Pharmaceuticals Announces Initiation of EPI-743 Pearson Syndrome Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 2 Jan 2014
Eisai Announces U.S. Availability of FYCOMPA(TM) (perampanel) CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 31 Dec 2013
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 31 Dec 2013
George S. Zorich Named Chief Executive Officer of Agilis Biotherapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Nov 2013
Eloxx Pharmaceuticals, Ltd. Announced the Initial Closing of its First Round of Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Nov 2013
Shire to Acquire ViroPharma in Strategic Move to Strengthen Rare Disease Portfolio; Will Augment Already Strong Growth Prospects
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 May 2012
Eisai Gains Positive CHMP Opinion for Fycompa(R) (perampanel) First in a New Class of Treatment for Partial Onset Epilepsy
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 23 Mar 2011
Asuragen Launches CE Marked IVD AmplideX(TM) Fragile X Test in Europe
Diagnostics Regulatory
 HSMN NewsFeed - 3 Sep 2010
Santhera and Ipsen Enter into Licensing Agreement for Fipamezole for the Treatment of Dyskinesia in Parkinson's Disease
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 24 May 2010
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 Jan 2010
PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
Biopharmaceuticals
 HSMN NewsFeed - 24 Aug 2009
Biovail to Acquire Rights to Develop, Commercialize JP-1730/Fipamezole in North America from Santhera
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jul 2008
Noven Announces Final FDA Approval of Stavzor(TM) for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jul 2008
Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 24 Jul 2008
Santhera Receives First Product Approval: Health Canada Approves Catena(R) for Treatment of Friedreich's Ataxia
Biopharmaceuticals Regulatory Neurology
 HSMN NewsFeed - 10 Apr 2008
COPAXONE(R) Significantly Reduced Annual Relapse Rates and Stabilized Disease Progression in Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Oct 2007
COPAXONE(R) Significantly Decreases Disease Activity in Patients Who Switched from Interferon Beta (IFNb) Due to Development of Neutralizing Antibodies (NAbs)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Oct 2007
Long-Term Study Shows COPAXONE(R) Significantly Slows Progression of Disability and Reduces Relapse Rates in Patients with Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2007
Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich's Ataxia and Provides Details on Study Design
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 Sep 2007
EnVivo Pharmaceuticals Announces Executive Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Aug 2007
European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 26 Jul 2007
Myriad Genetics Launches New Molecular Diagnostic Test
Diagnostics Oncology
 HSMN NewsFeed - 17 Jul 2007
Penwest Enters Into Collaboration Agreement With Edison Pharmaceuticals
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 7 Jun 2007
Teva and Active Biotech to Initiate Pivotal Phase III Trial Program of Oral Laquinimod for Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Jun 2007
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 May 2007
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Apr 2007
Data Published in Neurology Showed That Higher Dose of COPAXONE(R) Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Feb 2007
Valeant Pharmaceuticals Files Investigational New Drug Application for Cesamet(R) in Cancer Chemotherapy-Induced Neuropathic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Feb 2007
Valeant Pharmaceuticals Acquires Rights to Nabilone in United Kingdom and Europe
Biopharmaceuticals
 HSMN NewsFeed - 25 Jan 2007
Valeant Pharmaceuticals Developing Intranasal Diazepam for the At-Home Treatment of Emergency Seizures
Biopharmaceuticals Drug Delivery Neurology
 HSMN NewsFeed - 19 Jan 2007
Quest Diagnostics Announces Licensing Agreement for Genetic Testing Technology to Screen for Most Common Inherited Mental Impairment, Fragile X Syndrome
Diagnostics Licensing
 HSMN NewsFeed - 11 Oct 2006
Stonebridge Pharma and Capellon Pharmaceuticals Announce Co-Promotion Agreement to Market Symax(TM) Duotab (hyoscyamine sulfate) for Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 2 Oct 2006
Edison Pharma and Institute of Vision Enter Into Collaboration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 May 2006
Antipodean Pharmaceuticals Initiates Phase 2 Trial in Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 May 2006
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
Ataxia
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!